introduction: A comparative analysis of the efficacy of different cell candidates for the treatment of heart disease remains to be described. This study is designed to evaluate the therapeutic efficacy of 4 cell types in a murine model of myocardial infarction. methods: Bone marrow mononuclear cells (MN), mesenchymal stem cells (MSC), skeletal myoblasts (SkMb) and fibroblasts (Fibro) were isolated from male L2G transgenic mice (FVB background) that constitutively express firefly luciferase (Fluc) and green fluorescence protein (GFP). Cells were characterized by flow cytometry, bioluminescence imaging (BLI), and luminometry. Female FVB mice (n=60) underwent LAD ligation and were randomized into 5 groups to intramyocardially receive one cell type (5 x 10 5 ) or PBS as control. Cell survival was measured in vivo by BLI and ex vivo by TaqMan PCR at week 6. Cardiac function was assessed by echocardiography and invasive hemodynamic measurements were made at week 6.
INTRODUCTION
Coronary artery disease is the number one cause of morbidity and mortality in the US. Despite a wide range of therapeutic approaches, heart failure remains the leading cause of death in the Western world. 1 Recently, cell therapy has generated much enthusiasm as a novel potential treatment for ischemic heart disease. Numerous animal studies, each evaluating a particular class of cells for its regenerative potential in the infarcted heart, have been conducted. 2 Furthermore, the administration of skeletal myoblasts (SkMb) 3 , bone marrow-derived mononuclear cells (MN) [4] [5] [6] and mesenchymal stem cells (MSC) 7 as a therapy for end-stage heart disease has already been translated from bench top to bedside. Although the majority of experimental studies have shown encouraging results, clinical outcomes are divergent, which highlights the present imperfect understanding of the in vivo behavior and the mechanism(s) of action of the cells. 8 Moreover, differences in cell type and dose, study design, patient population, and timing of cell transplant hamper inter-study comparisons.
Recently, molecular imaging has proven to be a valuable tool to track cells on an in vivo and quantitative bases in mice. 9 As opposed to post-mortem histology, molecular imaging is noninvasive and facilitates repetitive imaging, thereby providing unprecedented insight into cell position and count. These characteristics make molecular imaging an extremely useful method to monitor cell survival, proliferation, migration, and even misbehavior. 10 In order to understand which cell type will generate optimal therapeutic responses, we evaluated the efficacy of various therapeutic stem cell candidates in a uniform, controlled murine model of ischemic heart failure. Results gathered from this head-to-head comparison study should yield valuable information regarding the optimal cell type for cardiac regenerative therapy.
METHODS
Transgenic l2G animals expressing fluc-GfP. All animal study protocols were approved by the Stanford Animal Research Committee. The donor group consisted of 8-week old male L2G mice (n=10), which were bred on FVB background and ubiquitously express green fluorescent protein (GFP) and firefly luciferase (Fluc) reporter genes driven by a β-actin promoter as previously described. 11 Recipient animals (n=70) consisted of syngeneic, female FVB mice (8 weeks old, Jackson Laboratories, Bar Harbor, ME, USA). To compare the efficacy of different adult stem cell types, animals were randomized into 5 recipient groups (n=12/group): (1) bone marrow derived mononuclear cells (MN), (2) skeletal myoblasts (SkMb), (3) bone marrow derived mesenchymal cells (MSC), (4) fibroblasts (Fibro), and (5) saline (PBS). To compare the effects of myocardial milieus on MN survival, animals were randomized into 2 recipient groups (n=5/group):
(1) injection at the infarct site and (2) injection at the peri-infarct site.
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Preparation of fibroblasts (fibro). Donor mice were euthanized by cervical dislocation after anesthesia with 5% isoflurane, and were placed in 70% ethanol for 5 minutes. For the isolation of Fibro, skin biopsies were taken from the tail and ears, minced, and incubated overnight in collagenase type II (400 U/mL, Gibco-Invitrogen, Carlsbad, CA, USA,), dissolved in DMEM (Gibco, NY, USA) supplemented with 20% heat-inactivated fetal bovine serum (FBS, Hyclone, Logan, UT, USA), 1% antibiotics/antimycotic solution (penicillin/streptomycin, Gibco-Invitrogen, Carlsbad, CA, USA) at 37°C and 5% CO 2 in air. 12 The next day, cells were dislodged from digested tissue by repeated pipetting and were passed through 70 µm sterile netting into sterile 14-ml centrifuge tubes. The samples were centrifuged for 5 minutes at 1200 rpm, and the cell pellet was resuspended in DMEM, 20% FBS, 1% penicillin/streptomycin to be plated in a 25 cm 2 tissue flask at 37°C/5%CO 2 .
Preparation of skeletal myoblasts (skmb).
After the skin was isolated, the muscles were dissected from the legs, minced, and placed in a Dispase solution (grade II, 2.4U/mL, Gibco-Invitrogen, Carlsbad, CA, USA) for 45 minutes under regular pipetting. The suspension was filtered through a 70 μm nylon mesh and was centrifuged at 1200 rpm for 5 minutes. The cell pellet was resuspended into 45% DMEM/45% Ham's F10 medium (Gibco-Invitrogen, Carlsbad, CA, USA), supplemented with 10% FBS and 1% penicillin/streptomycin and plated in 25 cm 2 collagen-coated tissue flasks. When confluent, cells were dislodged and passaged using PBS. Cells were grown for 5 passages, after which they were transferred into DMEM, 10% FBS, and 1% penicillin/streptomycin medium supplemented with 2.5 ng/mL Basic Fibroblast Growth Factor (Gibco-Invitrogen, Carlsbad, CA, USA) to achieve confluent SkMb cultures. 13
Preparation of bone marrow mononuclear cells (mn) and mesenchymal stem cells (msC).
Finally, the long bones were explanted, washed, and flushed with PBS using a 25-gauge needle to collect bone marrow. After passing through a 70 μm strainer, the isolate was centrifuged at 1200 rpm for 5 minutes, washed, and resuspended into DMEM, 20% FBS, and 1% penicillin/ streptomycin medium to grow MSC. All plated cells were allowed to grow for 6 passages before transplantation to avoid contamination with other cell types. To acquire the MN fraction, the bone marrow isolate was centrifuged for 40 minutes at 1600 rpm using a 14 mL tube with 3 mL Ficoll-Paque Premium (GE Healthcare, Piscataway, NJ, USA) gradient and 4 mL cell/saline suspension. MN were prepared freshly before application.
Characterization of stem cells by flow cytometry.
Cells were incubated in 2% FBS/PBS at 4°C for 30 min with 1 μL monoclonal FITC-conjugated antibodies against CD34, CD45, C-kit, CD11b, and CD90 (BD, San Jose, CA, USA), and processed through a FACSCalibur system (BD, San Jose, CA, USA) according to the manufacturer's protocol.
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In vitro firefly luciferase (fluc) assays. Cells were dislodged from culture flasks (SkMb, MSC and Fibro) or processed directly after isolation (MN) to be resuspended in PBS. Cell suspensions were divided into a 6-well plate in known concentrations. After administration of D-Luciferin (Xenogen, Alameda, CA, USA, 4.5ug/mL), peak signal expressed as photons per second per centimeter square per steridian (photons/s/cm 2 /sr) was measured using a charged coupled device (CCD) camera (IVS200, Xenogen, Alameda, CA, USA) as described. 14 
In vivo optical bioluminescence imaging (bli). BLI was performed using the IVIS 200
(Xenogen, Alameda, CA, USA) system. Recipient mice were anesthetized with isoflurane, shaved, and placed in the imaging chamber. After acquisition of a baseline image, mice were intraperitoneally injected with D-Luciferin (400 mg/kg body weight). Mice were imaged on day 2, 4, 7, and weekly until sacrifice at week 6. Peak signals (photons/s/cm 2 /sr) from a fixed region of interest (ROI) were evaluated as described. 11
Echocardiography to assess left ventricular fractional shortening (lvfs). Echocardiograp-
hy studies were performed 4 and 6 weeks post-operation. Three independent two-dimensional transversal-targeted M-mode traces were obtained at the level of the papillary muscles using a 14.7-MHz transducer on a Sequoia C512 Echocardiography system (Siemens, Malvern, PA, USA). Using the enclosed software, left ventricular end-diastolic and end-systolic posterior and anterior dimensions were measured by a blinded investigator (A.Y.S.) and processed to calculate left ventricular fractional shortening (LVFS). 92 | PART ii: ADUlT sTEm CElls -CHAPTER 6 measurement of hemodynamics with pressure-volume loops. Invasive, steady-state hemodynamic measurements were conducted by closed-chest pressure-volume (PV) loop analysis prior to sacrifice at week 6. The animal was placed under general anesthesia as described above. After midline neck incision, a 1.4-F conductance catheter (Millar Instruments, Houston, TX, USA) was retrogradally advanced through the right carotid artery into the left ventricle. The measurements of segmental conductance were recorded which allowed extrapolation of the left ventricular volume, which was coupled with pressure. These data were analyzed in a blinded fashion using PVAN 3.4 Software (Millar Instruments, Houston, TX, USA) and Chart/Scope Software (AD Instruments, Colorado Springs, CO, USA).
Ex vivo Taqman PCR. In our protocol, the transplanted cells were derived from male mice and were transplanted into female recipients, which facilitate quantification of male cells in the explanted female hearts by tracking the Sry locus found on the Y chromosome. After the invasive hemodynamic measurements at week 6, animals were sacrificed and hearts were randomly selected for explantation, followed by mincing and homogenization in 2 mL DNAzol (Invitrogen, Carlsbad, CA, USA). DNA was isolated according to the manufacturer's protocol. The DNA was quantified on a ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and 500 ng DNA was processed for TaqMan PCR using primers specific for the Sry locus. RT-PCR reactions were conducted in iCylcer IQ Real-Time Detection Systems (Bio-Rad, Hercules, CA, USA). Detection levels were compared to a standard curve to assess the number of viable cells per sample. All samples were conducted in triplets.
Postmortem histology. Hearts (n=3/group at week 2) were flushed with saline and placed in 2% paraformaldehyde for 2 hours at room temperature followed by 12-24 hours in 30% sucrose at 4°C. The tissue was embedded in Optical Cutting Temperature (OCT) Compound 
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Descriptive statistics included mean and standard error. Comparison between groups was performed using a one-way between groups ANOVA, or one-way repeated measures ANOVA when compared over time, and significance was assumed according to the Bonferroni-Holm's procedure.
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ADUlT sTEm CEll TyPEs foR TREATmEnT of myoCARDiAl isCHEmiA | 95 firefly luciferase (fluc) expression. After culturing for 6 passages, cells were processed for ex vivo BLI. Cell number correlated well with BLI signal in all groups (MN: r 2 =0.98, SkMb: r 2 =0.94, MSC: r 2 =0.94, Fibro: r 2 =0.93), indicating that BLI is a valid tool to assess cell viability. However, Fluc expression level differed per cell type, as MN showed poor ex vivo signal compared to other cell groups (figure 2a-b) . We hypothesized this was a consequence of the Ficoll selection in the MN group, which may have accounted for hibernation of the cells due to the hostile environment, thereby preventing proper D-Luciferin uptake. In order to test this hypothesis, we lysed the cells and measured intracellular Fluc enzyme. Our in vitro luminometry results indeed showed that the Fluc enzyme was present in all cell types and correlated well with cell number (MN: r 2 =0.99, SkMb: r 2 =0.95, MSC: r 2 =1.00, Fibro: r 2 =0.93) (figure 2c). It also correlated well with the ex vivo BLI findings (MN: r 2 =0.99, SkMb: r 2 =0.98, MSC: r 2 =0.90, Fibro: r 2 =0.95; figure 2d ).
Thus, BLI is a reliable tool to measure viable cell numbers ex vivo and can be used instead of in vitro luminometry. 
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In vivo kinetics and biodistribution of transplanted cells. In our study, increasing BLI signals in the MN group suggested a growing number of cells from day 2 to week 2 post-transplant.
Moreover, presence of extra-cardiac signals was consistent with migration to other organs such as the femur, spleen, and liver (figure 3a) . In contrast, for SkMB, MSC, and Fibro, BLI signals decreased acutely from day 2 to week 2. By week 4, the BLI signals equaled background level (figure 3b-e) . Interestingly, robust signals were seen at day 2 to day 4 in the lungs, suggesting leakage of SkMb, MSC, and Fibro with subsequent intracappillary retention. This might have accounted for the higher rates of acute-phase mortality in these groups (data not shown). In order to assess the effects of myocardial milieu on MN survival, we also compared infarct versus peri-infarct targeted injection. Similarly, we observed significant donor cell death after an initial increase in BLI signal and no major differences in the cell survival pattern between the two modes of injection after 4 weeks (figure 4). 
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ADUlT sTEm CEll TyPEs foR TREATmEnT of myoCARDiAl isCHEmiA | 97 figure 6b) . The LVFS in the PBS group was comparable with the literature. 18 Previously, it has been reported that cell transplantation accounted only for short-term preservation of cardiac function after MI. 19 In the present study, all cell groups showed decreased LVFS on week 6 compared to week 4.
These findings suggest that the beneficial effects of cell transplantation may last only for the acute post MI period. Transdifferentiation does not account for better cardiac performance. In our study, GFPexpressing MN could easily be found, confirming engraftment and BLI results (figure 7) . However, histological samples showed no overlay of donor-specific GFP, nucleus-specific DAPI, and cardiac specific troponin I and connexin 43 markers two weeks after transplantation. Thus, concordant with earlier findings 15, 20 , we have not observed MN-derived cardiomyocyte formation. Furthermore, we had difficulty identifying GFP-expressing SkMb, MSC, or Fibro, indicating that only very low counts of these cells were present in the heart (data not shown). 
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DISCUSSION
This study is the first to evaluate the efficacy of three different clinical cell candidates for the treatment of myocardial infarction, as compared to a cellular control (Fibro) and non-cellular control (PBS). Our major findings are as follow: (1) molecular imaging using the Fluc reporter gene is a reliable tool for monitoring donor cell survival, proliferation and migration in vivo; Most animal studies assessing the therapeutic potential of cell therapy have used conventional, post-mortem histological or RT-PCR techniques to gain insight in donor cell location and count. 2 However, these techniques cannot monitor the kinetics of cell migration or cell survival in the same subject in vivo. In this respect, studies have shown the possibility of labeling donor cells with iron particles or radioactive probes to image cell location in vivo. Unfortunately, iron particles are non-specific, as they can be ingested by macrophages following transplanted cell death 21 , and the relatively short half-lives of radioactive probes hamper long-term imaging of the cells. 9 By contrast, the current study demonstrates that molecular imaging of the Fluc reporter gene can provide longitudinal in vivo imaging of donor cell survival, proliferation, and migration and is in those aspects superior to the aforementioned imaging techniques. These advantages are a result of the stable genetic integration of the reporter gene (Fluc) in the donor cells, which are also equally transferred to progeny cells. As long as the donor/progeny cells are viable, transcription will lead to reporter gene mRNA followed by translation into reporter protein. Following systemic introduction, the reporter probe (D-Luciferin) will be catalyzed by all cells that have the reporter protein, leading to a signal which can be detected by a sensitive CCD camera. 22 However, due to the use of low-energy photons (2-3 eV), BLI is limited by photon attenuation and photon scattering within deep tissues. At present, this technique is not suitable for large animal or human studies. 23 Current studies in our laboratory are therefore aiming to combine multi-fusion reporter gene constructs (thereby enabling PET and BLI imaging) and iron labeling (for MRI). found evidence of MN migration to spleen and liver. 24 Splenic and hepatic homing of MN, as also observed in this study, is most likely due to leakage from the initial injection. This has been shown earlier using RT-PCR in mice 24 , SPECT imaging in large animal models 25 , and PET imaging in humans. 26 In fact, the BLI findings of MN homing resemble leukocyte scans, showing white blood cells are effectively attracted by the liver and spleen. 27 The mechanism by which these organs retain circulating MN may be attributed to chemoattractant properties of the tissue or the biological role that these organs have. For example, the liver expresses high levels of stromal derived factor-1 (SDF-1), which is a developmental and postnatal chemoattractant for stem cells. 28 This has been extrapolated to cardiac stem cell therapy by exogenous myocardial SDF-1 over-expression, which improved the rate of c-kit + cell homing and improved LV function in hearts with post-infarction LV remodeling. 29 In addition, increasing in vivo BLI signal during the first 2 weeks showed that MN were capable of either proliferation or homing in on the ischemic myocardium after an initial washout during this period of time, which was independent of injection site (infarct or peri-infarct). Although the survival pattern of MN was superior compared to other cell types, it must be stated that the cell number by TaqMan PCR at week 6 equaled ∼1,800 cells, representing only ∼0.4%
of the initially injected cell number. For MSC, we found the in vivo imaging signals to decrease dramatically within one week. This pattern concurs with the findings from others who found drastic MSC death between day 3 and 7 after myocardial delivery. 30 To date, there is intense investigative effort to uncover the mechanism by which stem cells may preserve the function of damaged hearts. Based on our current findings, the preservation of cardiac function by MN transplantation is not attributable to repopulation or transdifferentiation. Rather, the functional benefits of MN transplantation might be due to an augmentation of the natural process of myocardial healing by paracrine signaling and promoting neovascularization, among other factors. It has recently been shown that mice over-expressing MCP-1, which leads to an increased influx of MN into the damaged myocardium after infarction, had decreased infarcted areas and scar formation, and yielded better left ventricular function compared to wild-type mice. 31 Moreover, in the infarcted myocardium, CD11b + macrophages are an important source of cytokines and growth factors 32 and potential regulators of the extracellular matrix synthesis. 33 Specifically, transplantation of activated macrophages into the infarcted rat heart has been shown to accelerate vascularization and tissue repair and to improve cardiac remodeling and function. 34 Regarding paracrine signaling, bone marrow stem cells can secrete vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), angiopoetin-1 (Ang-1), and monocyte chemoattractant protein-1 (MCP-1), leading to an increase in collateral perfusion and cardiac function in pigs with myocardial infarction. 35, 36 Concordantly,
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ADUlT sTEm CEll TyPEs foR TREATmEnT of myoCARDiAl isCHEmiA | 103 results from the Doppler substudy of the REPAIR-AMI trial have recently shown clinical proof of restored microvascular function associated with an improved maximal vascular conductance capacity. 37 The clinical relevance of this study is significant. Different clinical trials have been conducted with divergent results that raise questions about which optimal cell type to use. 8 Although each cell type has its own advantages and limitations, our study is the first to detect a clear survival and modest functional benefit of MN compared to other clinical cellular candidates. However, questions remain regarding which portion of MN is responsible for the benefit, whether this benefit is transient, and whether a significant difference in cardiac function could translate into a clinical difference. These issues need to be addressed in future studies. Nevertheless, by using multi-modality evaluation, this study has demonstrated that MN confer a survival pattern in the infarcted mouse heart superior to those of SkMb and MSC. Moreover, MN exhibited a modest but transient preservation of cardiac function compared to cellular and non-cellular controls. Finally, our findings highlight the importance of being able to track stem cells in vivo and should be an impetus for further research on the development of clinically applicable molecular imaging techniques to closely follow stem cell fate in humans.
